Track topics on Twitter Track topics that are important to you
NORTHBROOK, Ill., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted molecular diagnostics, today reported financial and operating results for the second quarter ended June 30, 2015.
Nanosphere achieved record revenues for the second quarter 2015, of $4.7 million compared to $2.7 million in the second quarter 2014. This 76% year-over-year revenue growth was driven by U.S. based microbiology laboratories' continued adoption of our Gram Positive (BCGP) and Gram Negative (BCGN) blood culture tests, which grew more than 87% over Q2 2014. The Company also confirmed full year revenue guidance for 2015 of $18-20 million.
"We are pleased to report another consecutive quarter of record revenue and gross profit improvement. This progress is driven by a clear focus on execution and continued adoption of our Verigene system and its expanding menu though our U.S. customer base. In addition, we continue to make significant progress on our next generation Verigene system and expect to start clinical trials by year end," said Michael McGarrity, Nanosphere's president and chief executive officer. "We are confident that our growth and competitive position in the market will continue to advance driven by our best in class performance, differentiated clinical and economic utility provided by our proprietary flex panel design, and continued productivity in our sales, cost reduction and development efforts."
Gross margins increased to 49% in the second quarter of 2015 from 38% in the second quarter of 2014, driven by consumable cost reductions, coupled with lower royalty expenses due to the expiration of certain agreements. Sales, general and administrative expenses in the second quarter of 2015 decreased to $5.6 million from $6.7 million in the prior year period, and research and development expenses increased to $4.5 million in the second quarter of 2015, as compared to $4.0 million in the second quarter of 2014 due to continued investment in new product development
Net loss for the second quarter of 2015 was $8.6 million, as compared to $10.0 million in the second quarter of 2014.
Cash at June 30, 2015 was $23.9 million, with $3 million of this being restricted cash. Cash used in operations at the quarter ended June 30, 2015 was $13.7 million, compared to $18.6 million for the same period in 2014 due to a lower net operating loss.
|Conference Call & Webcast|
|Tuesday, August 11, 2015 @ 8:30am Eastern Time/5:30am Pacific Time|
|Replays – Available through August 25, 2015|
About the Verigene® System
The Verigene System uses Nanosphere's core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene assays target infections of the blood, respiratory tract and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, and reduced spread of antibiotic resistance.
About Nanosphere, Inc.
Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene ® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at: http://www.nanosphere.us.
Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere's ability to develop commercially viable products; (ii) Nanosphere's ability to achieve profitability; (iii) Nanosphere's ability to produce and market its products; (iv) Nanosphere's ability to obtain regulatory approval of its products; (v) Nanosphere's ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere's ability to obtain additional financing to support its operations. Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
|Statements of Operations and Comprehensive Loss|
|(dollars and shares in thousands, except per share data)|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Product sales||$ 4,718||$ 2,672||$ 9,336||$ 5,955|
|Costs and expenses:|
|Cost of sales||2,384||1,669||4,870||3,692|
|Research and development||4,469||3,950||8,109||9,171|
|Sales, general, and administrative||5,606||6,737||10,831||12,382|
|Total costs and expenses||12,459||12,356||24,323||25,245|
|Loss from operations||(7,741)||(9,684)||(14,987)||(19,290)|
|Other income (expense):|
|Total other expense||(854)||(362)||(1,140)||(726)|
|Net, and comprehensive loss||$ (8,595)||$ (10,046)||$ (16,127)||$ (20,016)|
|Deemed dividend on convertible preferred stock, due to beneficial conversion feature||(5,803)||$ --||(5,803)||$ --|
|Loss attributable to common shareholders||(14,398)||(10,046)||(21,930)||(20,016)|
|Net loss per common share - basic and diluted||$ (2.25)||$ (2.65)||$ (3.58)||$ (5.28)|
|Weighted average number of common shares outstanding - basic and diluted||6,392||3,795||6,128||3,791|
|(dollars in thousands, except per share data)|
|June 30, 2015||December 31, 2014|
|Cash and cash equivalents||$ 20,862||$ 21,053|
|Accounts receivable - net of allowance for doubtful accounts||3,392||4,292|
|Other current assets||580||380|
|Total current assets||38,624||35,112|
|Property and equipment - net of accumulated depreciation||5,119||5,072|
|Intangible Assets - Net of accumulated amortization||1,917||2,080|
|Total Assets||$ 45,735||$ 42,339|
|LIABILITIES AND EQUITY|
|Accounts payable||$ 3,391||$ 1,827|
|Other current liabilities||2,582||3,173|
|Debt - net||15,240||9,716|
|Total current liabilities||22,724||15,659|
|Convertible preferred stock, $0.01 par value; 10,000,000 shares authorized;|
|Series A: no shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively||—||—|
|Series B: 3,107 and 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively||1,633||—|
|Common stock, $0.01 par value; 150,000,000 shares authorized; 7,383,652 shares and 5,866,318 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively||74||59|
|Additional paid-in capital||459,337||448,527|
|Total stockholders' equity||23,011||26,680|
|Total liabilities and stockholders' equity||$ 45,735||$ 42,339|
CONTACT: Investors: Farzana Moinuddin, Interim Chief Financial Officer 847-400-9000 email@example.com Michael Rice, LifeSci Advisors 646-597-6979 firstname.lastname@example.orgNEXT ARTICLE
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...